Lonhala Magnair

  • Asthma/COPD

Lonhala Magnair Generic Name & Formulations

General Description

Glycopyrrolate 25mcg/mL; oral soln for inhalation.

Pharmacological Class

Long-acting anticholinergic.

How Supplied

Kit—60 vials (w. one Magnair device)


Generic Availability


Lonhala Magnair Indications


Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.

Lonhala Magnair Dosage and Administration


For oral inhalation use only with Magnair device. Administer at the same time of the day (AM + PM). Inhale contents of one vial (25mcg) twice daily.


Not established.

Lonhala Magnair Contraindications

Not Applicable

Lonhala Magnair Boxed Warnings

Boxed Warning

Lonhala Magnair Warnings/Precautions


Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Labor & delivery. Pregnancy. Nursing mothers.

Lonhala Magnair Pharmacokinetics

See Literature

Lonhala Magnair Interactions


Additive effects with concomitant other anticholinergic-containing drugs; avoid.

Lonhala Magnair Adverse Reactions

Adverse Reactions

Dyspnea, urinary tract infection, wheezing, upper respiratory tract infection, nasopharyngitis, peripheral edema, fatigue; paradoxical bronchospasm, hypersensitivity reactions.

Lonhala Magnair Clinical Trials

See Literature

Lonhala Magnair Note

Not Applicable

Lonhala Magnair Patient Counseling

See Literature